Kite Pharma Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;padding-top: 25px;;'>KP</div>
KITE -- USA Stock  

Last Earning Anouncement: 31st of March 2016  

Kite Pharma Stock News module provides quick insight into current market opportunities from investing in Kite Pharma. Use historical and current headlines to determine the investment entry and exit points. Many technical investors use Kite Pharma stock news signals to limit their universe of possible portfolio assets and to time the market correctly. Please see Stocks Correlation.

Search Today's Stock News

Kite Pharma stock news, alerts, and headlines are usually related to their technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Kite Pharma daily returns and investor perception about the current pice of Kite Pharma as well as its diversification or hedging effects on your existing portfolios.
Acquisition by Owen Witte of 2410 shares of Kite Pharma subject to Rule 16b-3
Filed transaction by Kite Pharma Inc director. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Kite Pharma insider trading alert for grant of common stock by Owen Witte, the corporate stakeholder, on 23rd of May 2020. This event was filed by Kite Pharma Inc with SEC on 2017-06-22. Statement of changes in beneficial ownership - SEC Form 4
Follow Benchmarks with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker

Price to Book

Price to Book Comparative Analysis

Kite Pharma is currently under evaluation in price to book category among related companies. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
 2014 2015 2016 2019 (projected)
Current Assets368.37 M631.09 M427.4 M384.66 M
Total Assets370.75 M707.96 M524.3 M471.87 M
Kite Pharma, Inc., a clinicalstage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products.
Please see Stocks Correlation. Please also try Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page